serine/threonine Kinase 17b (STK17B) (C-Term) Peptide
STK17B
Reactivity: Human
BP
Sodium azide
-
- Target See all DRAK2 (STK17B) products
- DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
- Protein Region
- C-Term
- Origin
- Human
- Application
- Blocking Peptide (BP)
- Characteristics
-
15 amino acids near the carboxy terminus of human DRAK2.
Human
-
-
- Application Notes
- DRAK2 peptide is used for blocking the activity of DRAK2.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 200 μg/mL
- Buffer
- PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1 % bovine serum albumin and 0.02 % sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C
- Expiry Date
- 12 months
-
- Target
- DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
- Synonyms
- zgc:65989 Peptide, STK17B Peptide, DRAK2 Peptide, Drak2 Peptide, 3110009A03Rik Peptide, AI120141 Peptide, serine/threonine kinase 17b (apoptosis-inducing) Peptide, serine/threonine kinase 17b Peptide, stk17b Peptide, STK17B Peptide, Stk17b Peptide
-
You are here:
